Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance
Frontiers in Microbiology · 10.04.2026 · 17
DOI: 10.3389/fmicb.2026.1779022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 10.04.2026. Verfasst von Victor Uchenna Chigozie und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology and Biotechnology, David Umahi Federal University of Health Sciences, Uburu, Ebonyi, Nigeria. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 267 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The accelerating crisis of antimicrobial resistance (AMR) necessitates strategies that extend beyond the continual discovery of new conventional antibiotics. Bacterial secondary metabolites, historically valued as sources of antimicrobial scaffolds, are increasingly recognized for their roles as resistance-modifying and anti-virulence agents. This review synthesizes key advances from 2020 to 2025 that reposition bacterial secondary metabolites as integral components of next-phase AMR intervention strategies. We examine their chemical and biosynthetic diversity, ecological functions, and molecular mechanisms of action, including efflux pump inhibition, β -lactamase suppression, interference with ribosomal protection, and disruption of biofilms and quorum-sensing networks. Mechanistic and evolutionary analyses are integrated to explain why many metabolites impose higher barriers to resistance development than single-target antibiotics. We further discuss contemporary discovery and optimization pipelines encompassing genome mining, multi-omics approaches, synthetic biology, and AI-assisted structure–activity modeling. Translational considerations are critically evaluated, with emphasis on pharmacokinetic and pharmacodynamic constraints, rational combination therapy design, preclinical validation, and emerging development pipelines. Regulatory, manufacturing, and commercialization challenges are addressed alongside opportunities enabled by nanocarrier delivery systems, microbiome-informed strategies, and personalized medicine. Overall, this review highlights bacterial secondary metabolites as evolution-resilient anti-resistance modalities capable of restoring and extending the efficacy of existing antibiotics, offering a pragmatic and mechanistically grounded path forward in combating AMR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology and Biotechnology, David Umahi Federal University of Health Sciences, Uburu, Ebonyi, Nigeria.
- Department of Pharmaceutical Microbiology and Biotechnology, Olivia University, Mukaza, Bujumbura, Burundi.
- Natural Products Bioprospecting and Translation Research Group (NaPBiTReG), International Institute of Pharmaceutical Research and Innovation (IIPRI), Uburu, Nigeria.
Zitieren
APA
Chigozie, V. U., & Esimone, C. O. (2026). Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1779022
Vancouver
Chigozie VU, Esimone CO. Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1779022
BibTeX
@article{Chigozie2026,
author = {Chigozie, Victor Uchenna and Esimone, Charles Okechukwu},
title = {Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1779022}
}
EUVIMED